Biogen
BIIB
1,009 hedge funds and large institutions have $29.6B invested in Biogen in 2021 Q4 according to their latest regulatory filings, with 144 funds opening new positions, 295 increasing their positions, 395 reducing their positions, and 153 closing their positions.
1.2% more ownership
Funds ownership: 83.05% → 84.25% (+1.2%)
6% less first-time investments, than exits
New positions opened: 144 | Existing positions closed: 153
3% less funds holding
Funds holding: 1,039 → 1,009 (-30)
15% less capital invested
Capital invested by funds: $35B → $29.6B (-$5.39B)
25% less repeat investments, than reductions
Existing positions increased: 295 | Existing positions reduced: 395
27% less funds holding in top 10
Funds holding in top 10: 15 → 11 (-4)
28% less call options, than puts
Call options by funds: $1.1B | Put options by funds: $1.52B
Top Buyers
Top Sellers
| 1 |
JP Morgan Chase
New York
|
-$275M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$255M |
| 3 |
ClearBridge Investments
New York
|
-$216M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$168M |
| 5 |
Primecap Management
Pasadena,
California
|
-$129M |
BIIB Hedge Fund Activity: Q4 2021 in Review
1,009 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q4 2021, worth a combined $29.6B — down 15% from $35B a quarter earlier.
Sellers outnumbered buyers: 153 funds closed out of BIIB and 144 opened new positions — a net loss of 9 holders — while 395 trimmed existing stakes and 295 added.
The largest buyer was Southeastern Asset Management, opening a new position worth an estimated $221M. The largest seller was JP Morgan Chase, cutting an estimated $275M.
- 1,009 institutional investors held Biogen (BIIB) as of Q4 2021, down from 1,039 in Q3 2021.
- Funds reported $29.6B of Biogen stock for Q4 2021, down 15% quarter-over-quarter.
- 144 funds opened new Biogen positions in Q4 2021 and 153 closed out, a net change of -9 holders.
- The largest Biogen buyer in Q4 2021 was Southeastern Asset Management, an estimated $221M added.
- The largest Biogen seller in Q4 2021 was JP Morgan Chase, an estimated $275M sold.
Based on aggregated 13F filings for Q4 2021.